期刊文献+

控释羟可酮的临床应用进展 被引量:3

Clinical application of controlled-release oxycodone
原文传递
导出
摘要 奥施康定是羟可酮的即释型与控释型的结合制剂,是阿片类长效止痛药。临床应用于中、重度癌痛与非癌痛,疗效相当于吗啡控释剂,等效止痛剂量约为吗啡的一半,不良反应较少。 Controlled-release oxycodone is a long-acting opioid analgesic drug. This drug is effective for moderate to severe pain caused by cancer and nonmalignant diseases, which is comparable with controlled-release morphine. It is approximately twice as potent as controlled-release morphine, a milligram per milligram basis, but with lesser adverse effects.
出处 《实用疼痛学杂志》 2006年第3期172-176,共5页 Pain Clinic Journal
关键词 羟可酮 疼痛 镇痛 Oxycodone Pain Analgesia
  • 相关文献

参考文献31

  • 1[1]Kaplan R,Parris WCV,Croghan M,et al.Decrease in opioid-related adverse experiences(AE) during chronic therapy with controlled -release oxycodone(OXYCR) in cancer pain patients.14th Annual Society.Los Angeles.CA.1995,Program Book,p.A146.
  • 2[2]Hales ME,Fleischman R,Salzmann R,et al.Efficacy and safety of controlled-release oxycodone compared with immediate-release oxycodone:a randomized,double-blind evaluation in patients with chronic back pain.Clin H Pain,2002,15:179-183.
  • 3[3]Kaiko RF,Benziger D.Cheng C,et al.Analgesic onset and potency of oral controlled-release (CR) oxycodone and CR morphine.Clin Pharmacol Ther,1996b,59:130.
  • 4[4]Mandema JW,Kaiko RF,Oshlack B,et al.Pharmacokinetic characterization of controlled-release oxycodone.Br J Clin Pharmacol,1996,42:747-775.
  • 5[5]Benziger DP,Miotto J,Grandy RP,et al.A pharmacokinetic/ pharmacodynamic study of controlled-release oxycodone.H Pain Sympt Mgmt,1997,13:75-82.
  • 6[6]Sunshine A,Olson NZ,Colon A,et al.Analgesic efficacy of controlled-release oxycodon postoperative pain.J Clin Pharmacol,1996,36:595-603.
  • 7[7]Mucci-LoRusso P,Berman BS,Silberstein PT.Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain:a randomized,double-blind,parallel-group study.Eur J Pain,1998,2:239-249.
  • 8[9]Heiskanen T,Olkkola KT,Kalso E.Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.Clin Pharmacol Ther,1998,64:603-611.
  • 9[10]Jannetto PJ,Wong SH,Gock SB.Pharmocogenomics as molecular autopsy for postmortem forensic toxicology; genotyping cytochrome P450 2D6 for oxycodone cases.J Anal Toxicol,2002,26:438-447.
  • 10[11]Portenoy RK.Managing cancer pain poorly responsive to systemic opiod therapy.Oncology(Hunting),1999,13 (5 Suppl 2):25-29.

二级参考文献4

  • 1王卫平,谢潞,郑继旺,蔡志基.大白鼠固定比率连续自身给药实验动物模型的建立[J].中国药物依赖性通报,1994,3(4):214-217. 被引量:12
  • 2Joranson DE, Ryan MK, Gilson AM, et al. Trends in medical use and abuse of opioid analgesics[J]. JAMA, 2000, 283(13):1710- 1714
  • 3David A,Fishbain MD. A typical withdrawal syncrome(organic delusional syndrome) secondary to oxycodone detoxification[J]. J Clin Psy chopharmacol, 1988,8(6) :441 - 442
  • 4Mierzejewski P, Koros E, Goldberg SR, et al. Intravenous self- administration of morphine and cocaine: a comparative study[J]. Poi J Pharmacol, 2003, 55(5) :713 - 726

共引文献10

同被引文献36

引证文献3

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部